Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Wilmington Pharmaceuticals Receives FDA Approval for Orally DisintegratingMetoclopramide Tablet

By Pharmaceutical Processing | September 9, 2009

Wilmington Pharmaceuticalsannounced today that the FDA has grantedmarketing approval for METOZOLV(TM) ODT (metoclopramide HCl), an orallydisintegrating formulation of metoclopramide for the treatment ofgastroesophageal reflux disease (GERD) and diabetic gastroparesis. Wilmingtonhas licensed METOZOLV ODT to Salix Pharmaceuticals, Inc., a specialtypharmaceutical company with a focus on gastrointestinal disorders. Wilmington Pharmaceuticals designed METOZOLV ODT to improve the deliverymode for patients who have difficulty swallowing pills or liquids due to theirdisease state. Orally disintegrating METOZOLV ODT tablets rapidly… melt on thetongue, thereby eliminating the need for swallowing pills with water,according to Eugene Haley, founder and CEO of Wilmington Pharmaceuticals.”We are extremely pleased to have achieved a significant milestone, theapproval of a patient-friendly formulation of an established drug thataddresses the needs of patients who cannot swallow traditional tablets,” Haleysaid. “As developers of rapid-dissolve formulations for proven drugs, weprovide our industry partners with significant potential for commercial gainwithout typical risks, costs, and time commitments associated with new drugdevelopment.” Salix Pharmaceuticals will market METOZOLV ODT under a licensing agreementwith Wilmington Pharmaceuticals. METOZOLV ODT is indicated for relievingsymptoms in adults with acute and recurrent diabetic gastroparesis and forshort-term therapy (4-12 weeks) in adults with symptomatic, documented GERDthat fails to respond to conventional therapy. “METOZOLV ODT offers a medically important option to physicians andpatients,” said Carolyn Logan, CEO of Salix Pharmaceuticals. “We are delightedto bring a patient-friendly formulation of this widely prescribed product tomarket.” “Wilmington Pharmaceuticals has proven to be a very reliable and efficientpartner in the development of this important new dosage form ofmetoclopramide,” Logan added.

Related Articles Read More >

Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE